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Abstract
Background: Hepatectomy is recommended as the most effective therapy for liver metastasis from colorectal
cancer (CRCLM). It is crucial to elucidate the prognostic clinicopathological factors.
Methods: Eighty-three patients undergoing initial hepatectomy for CRCLM were retrospectively analyzed with
respect to characteristics of primary colorectal and metastatic hepatic tumors, operation details and prognosis.
Results: The overall 5-year survival rate after initial hepatectomy for CRCLM was 57.5%, and the median survival
time was 25 months. Univariate analysis clarified that the significant prognostic factors for poor survival were depth
of primary colorectal cancer (≥ serosal invasion), hepatic resection margin (< 5 mm), presence of portal vein
invasion of CRCLM, and the presence of intra- and extrahepatic recurrence. Multivariate analysis indicated the
presence of intra- and extrahepatic recurrence as independent predictive factors for poor prognosis. Risk factors for
intrahepatic recurrence were resection margin (< 5 mm) of CRCLM, while no risk factors for extrahepatic recurrence
were noted. In the subgroup with synchronous CRCLM, the combination of surgery and adjuvant chemotherapy
controlled intrahepatic recurrence and improved the prognosis significantly.
Conclusions: Optimal surgical strategies in conjunction with effective chemotherapeutic regimens need to be
established in patients with risk factors for recurrence and poor outcomes as listed above.
Background
Despite recent improvements in the diagnosis and man-
agement of colorectal cancer (CRC), which have enabled
early detection followed by early treatment, many
advanced cases with hepatic or peritoneal metastasis are
still encountered. For further improvement of the prog-
nosis of CRC, it is particularly important to prolong the
survival of these advanced cases with distant metastasis.
Hepatectomy for liver metastasis from colorectal cancer
(CRCLM) is recommended as the most effective therapy
[1-11]. However, to date, 50% to 75% of patients develop
recurrence of the disease after curative resection of
CRCLM. Moreover, the cure rate by initial hepatectomy is
only 20% to 30% of cases [4-6,12]. Factors associated with
recurrence and prognostic determinants after initial hepa-
tectomy are still controversial. Recently, many studies
reported that the duration of survival is markedly
prolonged by effective chemotherapies, including the
molecular target drugs, for unresectable or recurrent
colorectal cancer [13,14]. Therefore, it is necessary to elu-
cidate predictive factors relevant to recurrence and survi-
val in order to determine optimal treatment strategies for
each patient with CRCLM.
The aim of this study was to retrospectively investigate
surgical outcomes in a consecutive series of patients
undergoing hepatectomy for CRCLM at a single institu-
tion, in order to analyze recurrence patterns and clinico-
pathological prognostic factors for survival.
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Patient selection
A retrospective study was conducted on 85 consecutive
patients undergoing initial hepatectomy for CRCLM for
curative intent at Osaka Medical College Hospital from
1995 to 2008. Clinical records and follow-up data were
obtained for 83 patients (55 men, 28 women). The mean
age at the initial hepatectomy was 66.5 ± 10.4 years
(range, 29-87 years). The mean observation period was
62.8 months (range, 4-129 months). Perioperative mor-
tality was not observed in patients in this study. All
patients signed appropriate informed consent for surgical
operation and to their inclusion in the study. The current
study was approved by the ethics committee of Osaka
Medical College Hospital. We also attest that this human
study undertaken as part of the research from which this
manuscript was derived is in compliance with the
Helsinki Declaration.
Characteristics of colorectal cancer
The primary tumor was in the colon in 60 cases (72.3%)
and in the rectum in 23 cases (27.7%). Among patients
with CRC, tumors were located in the right colon in 13
(15.7%), transverse colon in 9 (10.8%), and the left colon
in 38 (45.8%). Sixty-three percent of the primary tumors
had involved regional lymph nodes, and 46.8% and
51.9% had well- or moderately-differentiated histology,
respectively. The histological depth of invasion in the
colorectal wall is denoted as follows: se, serosa; ss, sub-
serosa; a1, sub-adventitia; a2, adventitia. In 58 patients
(71.6%), the depth of the primary tumors was within
subserosal layer (≤ ss (a1)) of the colorectal wall.
Hepatectomy
In this series, hepatectomy was indicated for CRCLM
when the following 3 conditions were met: (1) the pri-
mary CRC was curatively resected; (2) metastasis located
only in the liver; and (3) no limitation regarding the
number or size of CRCLM as far as hepatic functional
reserve was warranted after hepatectomy. All hepatec-
tomies were performed by three experienced hepatobili-
ary surgeons (MH, FH, and NT) during the study
period. All patients received potentially curative hepa-
tectomy with removal of gross tumor with a negative
macroscopic margin. With respect to hepatic hilar
lymph nodes, lymph node dissection is not routinely
performed, since node-positive cases in this region were
strongly associated with extremely poor survival in our
previous experience (data not shown).
Synchronous (as opposed to metachronous) CRCLM
was defined as simultaneous presentation of liver metas-
tasis at the time of CRC operation, and was detected in
28 patients (33.7%). They received either synchronous
or metachronous hepatectomy, mainly based on the
each patient’s condition and need.
Generally, partial or non-anatomical hepatectomy was
performed, whereas systemic or anatomical hepatectomy
was preferred in cases when this procedure had advan-
tage in terms of operation time, blood loss, safety, and
invasiveness. Hepatic resection was performed following
as t a n d a r dt e c h n i q u ea sp r e v i o u s l yr e p o r t e d[ 1 5 ] .A n
ultrasonic dissector (SonoSurg system; Olympus Inc.,
Tokyo, Japan) was used for parenchymal transection,
and small vessels were ligated or coagulated using soft-
coagulation system or bipolar electrocautery. During the
resection procedure, surgical margin was carefully
confirmed using intraoperative ultrasonography in order
to obtain a general surgical margin of 5-10 mm. Thus,
in 63.6% of cases, hepatic surgical margin was wider
than or equal to 5 mm.
Chemotherapy
With respect to chemotherapy before hepatectomy and
adjuvant chemotherapy after hepatectomy, the eligibility
criteria in this series included histologically-proven ade-
nocarcinoma of the colon or rectum. Patient criteria
included an Eastern Cooperative Oncology Group
(ECOG) performance status of 0-2. Additionally,
patients had to have no serious or uncontrolled concur-
rent medical illness; no active infection; adequate hema-
tologic parameters (WBC > 4.0 × 10
3/L, platelet
count > 100 × 10
9/L), renal functions (serum creatinine
≤ 1.2 mg/dL or calculated creatinine clearance by Cock-
roft formula ≥ 50 mL/min), or hepatic functions (total
bilirubin < 2.0 mg/dL and aspartate aminotransferase,
alanine aminotransferase < 100 IU/L). Regimens con-
sisted of 5-Fluorouracil (5-FU) alone, 5-FU/leucovorin
(LV), 5-FU/cisplatin, tegafur plus uracil (UFT) alone,
UFT/LV, oteracil (TS-1), FOLFOX (infusional 5-FU/LV
+ oxaliplatin), FOLFIRI (infusional 5-FU/LV + irinote-
can) and IFL (5-FU/LV + irinotecan). Thus, 35 patients
(42.2%) received chemotherapy before hepatectomy and
56 patients (71.8%) received adjuvant chemotherapy
after hepatectomy.
Patient follow-up
Patients were examined for CRCLM recurrence by ultra-
sonography and contrast enhanced computed tomogra-
phy (CT) every 4-6 months and blood tests including
tumor markers, such as carcinoembryonic antigen
(CEA), every 2-3 months after discharge. When recur-
rence was suspected, magnetic resonance imaging was
performed to ensure the appearance of new lesions in
the remnant liver, while systemic recurrence was exam-
ined by fluorodeoxyglucose-positron emission tomogra-
phy or Gallium scintigraphy. Chest and pelvic CT was
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pulmonary metastasis or recurrence. Recurrence was
diagnosed when at least two imaging studies confirmed
the new lesions showing typical features of CRC/
CRCLM, compared to the previous images. The recur-
rent CRCLM were treated by repeat hepatectomy when
applicable (n = 15), otherwise by systemic chemother-
apy, or their combination. During the study period, no
major changes in clinical aspects were undertaken
except for the use of more potent chemotherapeutic
agents applied in the recent patients, with other surgical
techniques and perioperative patient management being
carefully conserved so as to minimize possible bias.
Clinicopathological analysis
Patient demographics, laboratory tests including tumor
markers, tumor characteristics, treatment, recurrence,
and survival data were analyzed to determine prognostic
factors in terms of 3- and 5-year survival rates after the
initial hepatectomy for CRCLM. The surgically resected
specimens were studied macro- and microscopically to
determine the various tumor characteristics including
size of the largest tumor, number of tumors, morphol-
ogy and extent of the tumor, and surgical margin. For
microscopic analysis, the resected specimens were fixed
in 10% formaldehyde and sliced into 5-mm sections.
After each section was sliced into 5 -μm tissue sections
and stained with hematoxylin and eosin, two specialists
of pathology (YS, AT) reviewed for histological confir-
mation of the pathological diagnosis. In this study, sur-
gical margin status was defined as the distance of the
lesion closest to the cut surface of the liver, and macro-
scopically classified into two categories: a surgical mar-
gin of 5 mm or wider (≥ 5 mm), and narrower than
5 mm (< 5 mm).
Statistical analysis
Actuarial survival rate was calculated by the Kaplan-Meier
method. Univariate analyses were performed using the
log-rank test. Multivariate analyses were performed by
Cox proportional hazards regression. Statistical compari-
sons were made by Fisher’s exact probability test. A differ-
ence was regarded as statistically significant at P <0 . 0 5 .
Results
Primary colorectal tumor characteristics
Tumor characteristics of primary CRC were analyzed for
prognostic values (Table 1). Included were: tumor loca-
tion (colon or rectum), tumor differentiation (well, mod-
erately, or poorly differentiated adenocarcinoma),
number of lymph nodes metastasis, depth of tumor
invasion in the colorectal wall (≤ ss (a1) or ≥ se (a2); ss,
sub-serosa; se, serosa; a1, sub-adventitia; a2, adventitia),
lymphatic invasion, venous invasion, and Duke’ss t a g e ;
the only significant difference in survival rate was
observed between patients with primary CRC ≤ ss (a1)
and those with ≥ se (a2) in the colorectal wall
(P = 0.0133).
Time of liver metastasis and timing of hepatectomy
Among 83 patients receiving hepatectomy for CRCLM,
13 (15.7%) patients received synchronous liver and
colorectal resection, and 70 (84.3%) patients received
metachronous resection (Table 1). The 3- and 5-year
survival rates were 70.5% and 70.5% in 13 patients with
synchronous resection, 61.5% and 55.2% in 70 patients
with metachronous resection. No differences in survival
rates between these two groups were noted (P = 0.4927).
Synchronous CRCLM was detected at the time of CRC
operation in 28 patients (33.7%). Hepatectomy was done
synchronously in 13 and metachronously in 15 patients.
The 5-year survival rate was 70.5% in 13 patients with
synchronous resection, and 54.2% in 15 patients with
metachronous resection. No differences in survival rates
between these two groups were noted (P = 0.6547).
Moreover, timing of hepatectomy was not associated with
intra- and extrahepatic recurrence (P = 1.0000).
Metastatic liver tumor characteristics
The mean and the median sizes of the largest metastatic
lesions were 3.58 ± 1.93 cm and 3.0 cm, respectively. Of
83 patients, 47 patients (56.6%) underwent resection for
solitary metastasis, 27 patients (32.5%) for 2 or 3
tumors, and 9 patients (10.8%) had 4 or more tumors
resected (Table 1). In 63 patients (75.9%), the tumor
location was unilobar (right in 36, left in 27), and
20 patients (24.1%) had bilobar disease resected. There
were no significant differences in terms of the number,
maximal size, and distribution of CRCLM (P = 0.3868,
0.9255, and 0.1882, respectively). The serum value of
CEA immediately before hepatectomy was not asso-
ciated with subsequent survival rate. Portal vein invasion
was observed in 8 patients (9.8%) with the significantly
worse 3- and 5-year survival when compared with those
without portal invasion (28.6% and 0% vs. 66.2% and
63.4%, respectively, P = 0.0074; Figure 1). However,
there was no significant correlation between portal vein
invasion and intrahepatic recurrence rate (P = 0.7072).
Operation-related parameters
With regard to the type of hepatectomy (anatomic, 44;
non-anatomic, 39) and extent of resection (< lobectomy,
62; ≥ lobectomy, 21), no differences in survival rates
between these groups were noted (P = 0.4862, 0.0875,
respectively, Table 1).
Compared with the patients with a hepatic surgical
margin ≥ 5 mm (n = 49, 63.6%), the 3- and 5-year survi-
val rates for those with resection margin < 5 mm (n = 28,
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Factor Number of
patients
3-year survival rate
(%)
5-year survival rate
(%)
Univariate
P-value
Multivariate
P-value
Sex 0.9217
Male 55 61.1 57.0
Female 28 65.9 58.6
Location of CRC
Rt-hemicolon 13 38.1 38.1
Transverse colon 9 75.0 56.3
Lt-hemicolon 38 58.8 53.9
Any colon 60 57.0 50.7 0.0794
Rectum 23 81.3 81.3
Depth of CRC 0.0133 0.3183
< ss (a1) 58 70.0 66.5
≥ se (a2) 23 47.3 39.4
Tumor differentiation of CRC 0.4712
Well 37 70.4 65.0
Moderate 41 53.3 48.0
Poor 1 100.0 100.0
Lymphatic invasion of CRC 0.7469
Present 66 62.6 62.6
Absent 14 73.5 45.9
Venous invasion of CRC 0.4259
Present 63 67.2 64.2
Absent 18 55.6 41.7
Lymph node metastasis of CRC 0.6040
0 30 70.9 57.8
1~3 39 64.0 64.0
≥4 13 48.4 48.4
Present 52 59.7 59.7 0.6779
Absent 30 70.9 57.8
Duke’s stage of CRC 0.4376
A 7 80.0 80.0
B 11 60.6 22.7
C 33 60.2 60.2
D 30 65.0 65.0
Age at hepatectomy 0.5150
< 50 years 6 66.7 66.7
≥50 years 77 64.5 57.0
CEA before hepatectomy 0.2441
< 5 ng/ml 27 53.9 49.4
≥ 5 ng/ml 54 68.7 62.4
Time of liver metastasis 0.7865
Synchronous 28 61.2 61.2
Metachronous 55 63.7 56.8
Timing of hepatectomy 0.4927
Synchronous 13 70.5 70.5
Metachronous 70 61.5 55.2
Method of hepatectomy 0.4862
Anatomical 44 62.1 55.9
Non-anatomical 39 63.2 59.0
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70.4% and 64.5% vs. 47.8% and 41.8%, respectively P =
0.0399; Figure 2). During hepatic parenchymal resection,
tumors were exposed on the cut surface of the liver in 6
patients (7.3%); however, the survival of those patients
was not significantly different from the other patients
without tumor exposure.
Intra- and extrahepatic recurrence after initial
hepatectomy
Recurrence was detected in 52 (65.0%) of the patients
who underwent hepatectomy (Table 1). The site of the
first recurrence was the liver in 32 (41.0%) patients.
Twenty-six (32.5%) patients had extrahepatic recurrence;
the lung in 18, the peritoneal cavity or local recurrence in
9, the brain in 2, and the bone in 1. Patients with recur-
rent hepatic metastasis after initial hepatectomy (n = 37,
44.6%) had a significantly worse survival than those with-
out hepatic recurrence (n = 46, 55.4%, P = 0.0104). More-
over, patients with recurrent extrahepatic metastasis after
initial hepatectomy had a significantly worse survival
than those without extrahepatic recurrence (P =0 . 0 2 1 7 ) .
Especially, those with lung metastasis after hepatectomy
had extremely poor survival (3 years, 39.9%; 5 years, 0%).
Risk factors for intra- and extrahepatic recurrence were
analyzed. On uni- and multivariate analysis, hepatic
resection margin (< 5 mm) was significantly associated
with intrahepatic recurrence after initial hepatectomy
Table 1 Analysis of clinicopathological factors for prognosis (Continued)
Extent of hepatectomy 0.0875
< Lobectomy 62 67.1 63.8
≥ Lobectomy 21 46.5 31.0
Number of CRCLM 0.3868
Solitary 47 69.3 61.0
Multiple 36 51.8 51.8
Location of CRCLM 0.1882
Unilobar 63 68.9 62.6
Bilobar 20 32.2 32.2
Size of CRCLM 0.9254
< 3 cm 42 71.3 62.9
3 - 5 cm 26 51.8 51.8
≥ 5 cm 14 50.4 50.4
Resection margin of CRCLM 0.0399 0.3917
< 5 mm 28 47.8 41.8
≥ 5 mm 49 70.4 64.5
Portal vein invasion of CRCLM 0.0074 0.2689
Present 8 28.6 0
Absent 74 66.2 63.4
Intrahepatic recurrence 0.0104 0.0051
Present 32 44.6 32.5
Absent 46 75.1 75.1
Extrahepatic recurrence 0.0217 0.0064
Present 26 43.1 43.1
Absent 54 69.4 63.0
Lung recurrence 0.1349
Present 18 39.9 -
Absent 62 66.1 60.3
Chemotherapy before
hepatectomy
0.0991
Present 35 51.1 43.8
Absent 48 72.7 68.6
Chemotherapy after hepatectomy 0.3617
Present 56 63.6 60.3
Absent 22 52.8 45.2
CRC: colorectal cancer, CRCLM: liver metastasis from colorectal cancer, CEA: carcinoembryonic antigen.
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extrahepatic recurrence were identified (data not shown).
Perioperative chemotherapy
Thirty-five patients (42.2%) received chemotherapy before
initial hepatectomy, and 56 patients (71.8%) received che-
motherapy after hepatectomy. Overall, the presence or
absence of chemotherapy, regardless of chemotherapy
before or after hepatectomy, or the combination, was not
associated with intra- or extrahepatic recurrence or survi-
val (Tables 1, 2). In subgroup analysis, in 55 patients with
metachronous CRCLM, chemotherapy before and/or after
hepatectomy was not associated with recurrence or the
prognosis (Tables 3, 4). On the contrary, in 28 patients
Figure 1 Survival curves according to portal vein invasion in the resected liver specimen. No portal vein invasive disease is denoted as “port
(-)”. Invasion confined to the portal vein is arbitrarily designated as “port (+)”. Portal vein invasion was observed in 8 patients with the significant
worse 3- and 5 year survival when compared with those without portal invasion (28.6% and 0% vs. 66.2% and 63.4%, respectively, P = 0.0074).
Figure 2 Survival curves according to surgical margin in the resected liver specimen. A surgical margin of 5 mm or wider is denoted as
“≥ 5m m ”. A surgical margin narrower than 5 mm is denoted as “<5m m ”. Patients with a surgical margin of 5 mm or wider had a better
survival rate than those with a narrower resection margin (P = 0.0399).
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hepatectomy was significantly associated with lower intra-
hepatic recurrence rate (P = 0.0087) and better prognosis
(P = 0.0458) after initial hepatectomy, but not for extrahe-
patic recurrence (Tables 5, 6).
Patient survival and prognostic factors
The survival time ranged from 4 months to 129 months,
mean survival time was 36.5 + 28 months, and median
survival time was 25 months. The 5-year survival rate
for the 83 patients after initial hepatectomy was 57.5%,
Table 2 Risk factors for intrahepatic recurrence after initial hepatectomy
Factor Number of patients Univariate P-value Multivariate P-value
Location of CRC 0.0733
Colon 27
Rectum 5
Depth of CRC 0.2112
< ss (a1) 19
> se (a2) 12
Tumor differentiation of CRC 0.4618
well 13
moderate 16
poor 1
Lymphatic invasion of CRC 1.0000
Present 25
Absent 5
Venous invasion of CRC 0.7765
Present 23
Absent 7
Lymph node metastasis of CRC 0.6320
Present 21
Absent 10
Time of liver metastasis 0.8151
Synchronous 12
Metachronous 20
Timing of hepatectomy 1.0000
Synchronous 6
Metachronous 26
Number of CRCLM 0.3516
Single 16
Multiple 16
Size of CRCLM 0.1218
< 5 cm 23
≥ 5c m 8
Portal vein invasion of CRCLM 0.7072
Present 4
Absent 27
Surgical margin of CRCLM 0.0228 0.0133
< 5 mm 15
≥ 5m m 1 3
Chemotherapy before hepatectomy 0.4837
Present 15
Absent 17
Chemotherapy after hepatectomy 0.1976
Present 19
Absent 12
CRC: colorectal cancer, CRCLM: liver metastasis from colorectal cancer.
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58% [4,6-8,10-12,16,17]. Prognostic factors analyzed are
shown in Table 1. On univariate analysis, tumor depth
of CRC (≤ ss (a1) vs. ≥ se (a2)), portal vein invasion of
CRCLM, macroscopic hepatic resection margin (< 5
mm vs. ≥ 5 mm), and the presence of intra- and extra-
hepatic recurrence were associated with a significant dif-
ference in survival rate after initial hepatectomy (P =
0.0133, 0.0074, 0.0399, 0.0104, and 0.0217, respectively,
Table 1, Figure 3). Multivariate analysis revealed that
independent prognostic factors for poor outcome were
t h ep r e s e n c eo fi n t r a -a n d / o re x t r a h e p a t i cr e c u r r e n c e
(P = 0.0051, 0.0064, respectively, Table 1).
Discussion
While untreated CRCLM has a poor prognosis with
median survival ranging from 6 to 12 months and is not
expected to be over 5 years, long-term survival and
potential for cure following surgical resection for
CRCLM had been demonstrated in numerous uncon-
trolled studies [7,8,12]. These studies reported that the
overall 5-year survival rates are in the range of 20% to
58%, and the median survival times are 24-46 months
[4,6-8,10-12,16,17]. However, it has also been reported
that 57% to 78% of those patients will develop a recur-
rence of the disease in the hepatectomy series, and
intrahepatic recurrence occurs in approximately 50% of
patients [4,6,9,18]. It has been considered that occult
metastasis surfacing from the primary CRC and residual
lesion scattered from liver metastasis are the two major
pathways through which hepatic recurrence of meta-
static lesion occurs after initial hepatectomy [19,20].
Therefore, treatment strategies including hepatic resec-
tion should be determined on the basis of these
mechanisms for recurrence of metastasis. In Japan,
surgical procedures for CRCLM are recommended if the
following conditions are met: (1), the primary tumor
was curatively resected; (2), metastasis is located only in
the liver; (3), the patient is in a condition to be able to
bear hepatectomy; and relative indications include: (4),
extrahepatic metastasis can be controlled when present;
and (5), reductive operation is a part of multimodal
treatment [21]. However, the detailed consensus in
terms of ideal timing, type, and extent of hepatectomy
and optimal combination with perioperative chemother-
apy are not currently provided with sufficient evidence.
The aims of this study are to retrospectively evaluate
the significant prognostic factors for survival and risk
factors for recurrence in patients who underwent hepa-
tectomy, and thereby to determine the optimal timing
and method of hepatectomy with concurrent use of
perioperative chemotherapy.
In the present study, prognostic factors on univariate
analysis were the depth of the primary CRC, portal vein
invasion and surgical margin at hepatectomy for
CRCLM, and the presence of intra- and extrahepatic
recurrence after the initial hepatectomy. Independent
prognostic factors on multivariate analysis were the pre-
sence of intra- and extrahepatic recurrence. Of these
factors, the portal vein invasion and surgical margin sta-
tus at hepatectomy are important factors through which
surgery can improve prognosis.
There have been several reports on the risk factors of
intra- and extrahepatic recurrence [7,22-24]. In the pre-
sent study, an independent risk factor for intrahepatic
recurrence was the hepatic resection margin, while there
were no risk factors regarding extrahepatic recurrence.
Hematogenous dissemination of CRC was reported to
be significantly associated with the size of liver meta-
static nodules by the cascade theory [25]. In this theory,
Table 3 Effect of peri-operative chemotherapy on survival for metachronous CRCLM
Number of patients 3-year survival rate (%) 5-year survival rate (%) Univariate P-value
Chemotherapy before hepatectomy
Present 32 53.2 45.6 0.1872
Absent 23 80.0 72.8
Chemotherapy after hepatectomy
Present 36 57.9 53.1 0.7919
Absent 15 72.2 61.9
Table 4 Effect of peri-operative chemotherapy on recurrence for metachronous CRCLM
Intrahepatic recurrence P-value Extrahepatic recurrence P-value
Present Absent Present Absent
Chemotherapy before hepatectomy Present 12 17 1.0000 13 18 0.2394
Absent 8 13 5 16
Chemotherapy after hepatectomy Present 14 19 1.0000 13 22 0.5335
Absent 6 9 4 11
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to the lung and subsequently to the other organs, the
size of CRCLM is thought to increase. However, the
present study did not include the size or the number of
CRCLM as risk factors for intra- or extrahepatic recur-
rence, implicating the significance of surfacing microme-
tastasis from the primary CRC which could not be
detected perioperatively.
The surgical margin of < 5 mm at hepatectomy was
detected as a risk factor for subsequent intrahepatic
metastasis in this study. The role of surgical margin sta-
tus as a prognostic factor to predict posthepatectomy
survival has been controversial [24,26-29], and in the
largest single-center series, Are et al. reported that a
margin width > 1 cm was an independent predictor for
better survival and is optimal [28]. Nuzzo et al. also
recently reported that a histological surgical margin of ≤
5 mm was associated with lower overall and disease-free
survival rates independent of other clinic-pathologic fac-
tors [29]. In contrast, Bodingbauer et al. demonstrated
that the rate of recurrence at the surgical margin was
low and a positive margin was not associated with an
increased risk of recurrence either at the surgical margin
or elsewhere, if hepatectomy was performed with ultra-
sonic dissector by experienced surgeons [24]. The pre-
sent study is distinct from previous studies because
macroscopic, instead of histological, surgical margin uti-
lized as a parameter. A macroscopic surgical margin
rather than microscopic margin was adopted, since 1)
use of various dissection and coagulation devices, such
as soft-coagulation system, ultrasonic dissector, and
bipolar electrocautery during hepatic parenchymal trans-
ection [15], would potentially hinder an accurate assess-
ment regarding pathological surgical margin status
including R0 (no residual tumor) and R1 (microscopic
residual tumor) status [24,29]; and 2) the macroscopic
surgical margin was considered a better parameter of
clinical usefulness for patient and treatment selection.
Namely, during preoperative evaluation, whether a sur-
gical margin of ≥ 5 mm was macroscopically feasible or
not, it was utilized as a practical marker to determine
which was indicated first as an initial therapy for each
patient: hepatectomy or neoadjuvant chemotherapy. If
the surgical margin was estimated to be < 5 mm, preo-
perative chemotherapy is the best option [30]. It does
need to be noted that resection should not be precluded
whatever the width of the surgical margin, since no
other single treatment modality can surpass hepatect-
omy even with a 0- to 1-cm surgical margin [28]. In the
present study, surgical margin status was determined as
a prognostic factor on univariate, but not on multivari-
ate analysis. These findings are in accordance with the
report by Kokudo et al. that found the surgical margin
was correlated with tumor recurrence but not with sur-
vival rate [26]. However, when an insufficient surgical
margin is suspected during hepatectomy, or postopera-
tive pathology of the resected specimen reveals inade-
quate surgical margin, adjuvant chemotherapy should be
started to prevent intrahepatic recurrence, though a pro-
spective study on this approach is necessary to make
definite conclusions.
Portal vein invasion in the resected liver was observed
in a small number of patients (9.8%), but also showed
significant negative impact on survival, suggesting it
could reflect the grade of aggressiveness and invasiveness
of each tumor or the potential for intrahepatic microme-
tastases, as has been implicated by some authors [29,31]
in the context of surgical margin status as a surrogate
marker for malignant potential. Therefore, optimal sur-
gery should include a strategy against portal vein
Table 5 Effect of peri-operative chemotherapy on survival for metachronous synchronous CRCLM
Number of patients 3-year survival rate (%) 5-year survival rate (%) Univariate P-value
Chemotherapy before hepatectomy
Present 3 33.3 0 0.2267
Absent 25 66.0 66.0
Chemotherapy after hepatectomy
Present 20 76.5 76.5 0.0458
Absent 7 0 0
Table 6 Effect of peri-operative chemotherapy on recurrence for synchronous CRCLM
Intrahepatic recurrence P-value Extrahepatic recurrence P-value
Present Absent Present Absent
Chemotherapy before hepatectomy Present 3 0 0.0672 03 0.5360
Absent 9 16 8 17
Chemotherapy after hepatectomy Present 5 15 0.0087 81 2 0.0681
Absent 6 1 0 7
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Page 9 of 12invasion, such as anatomical hepatic resection including
Glisson’s sheath with a sufficient margin, and aggressive
adjuvant chemotherapy for this subgroup of patients
[32]. Further studies are needed to clarify its clinical
significance.
Regarding the timing of hepatectomy for synchronous
CRCLM, controversy remains on whether to perform
simultaneous resection or to include an observation per-
iod for a couple of months. No differences between
these two approaches were detected in the present
study, suggesting that in synchronous situations, surgery
should be planned at least before hepatic tumor(s)
become unresectable and that patients need to be trea-
ted with adjuvant chemotherapy immediately, since
this subgroup appeared to benefit from adjuvant
chemotherapy.
A further point of concern is multiple bilobar CRCLM
lesions which precipitate the most challenging situation
for hepatic surgeons. Although some portion of this
patient cohort would indeed benefit from aggressive
chemotherapy and subsequent hepatectomy after
successful down-sizing of those lesions, many of these
patients are not candidates for surgical intervention.
Appropriate application and adequate combination of
modalities, such as radiofrequency ablation [33], percu-
taneous transhepatic portal embolization [34], and two-
stage hepatectomy are expected to extend the surgical
indication for these patients [35].
There is not yet a sufficient consensus as to whether
the perioperative chemotherapy is significantly asso-
ciated with disease-free survival or prognosis [36]. In the
present report, a combination of surgical therapy and
adjuvant chemotherapy after hepatectomy controlled
intrahepatic recurrence and consequently improved the
prognosis significantly, but only in the subgroup with
synchronous CRCLM. Conversely, in the patient sub-
group with synchronous CRCLM, adjuvant chemother-
apy would be essential. As for metachronous disease, no
benefits from chemotherapy were detected in this study.
However, it should be noted that the chemotherapy in
the present series mainly depended on UFT + LV, TS-1,
FOLFOX and FOLFIRI, and the recently developed
molecular targeting agents, such as bevacizumab and
cetuximab, which have been reported to improve the
prognosis of recurrent and unresectable CRC [14,37-39],
were not included in this study. Since use of these
newer chemotherapeutic agents before hepatectomy is
expected to control recurrence by extermination of the
micro cancer cell, a similar study is currently being con-
ducted on those patients who received these newer che-
motherapeutic agents.
Conclusions
In CRCLM, intra- and extrahepatic recurrence were
independent prognostic factors, and independent risk
factors for intrahepatic recurrence included macroscopic
resection margin during hepatectomy. Combination of
surgery and adjuvant chemotherapy for synchronous
CRCLM could control intrahepatic recurrence and sig-
nificantly improve prognosis. Considering the outcomes
of treatment for CRCLM are not yet satisfying, extermi-
nation of the micro cancer cell should be achieved by
introduction of more potent chemotherapeutic agents in
combination with optimal surgery. Further studies are
needed to clarify this matter.
Figure 3 Survival curves according to the presence of
intrahepatic recurrence after the initial hepatectomy. The
presence of recurrence is denoted as “(+)” and absence “(-)”. The
presence of intrahepatic recurrence were associated with a
significant difference in survival after initial hepatectomy (P =
0.0104).
Figure 4 Survival curves according to the presence of
extrahepatic recurrence after the initial hepatectomy. The
presence of recurrence is denoted as “(+)” and absence “(-)”. The
presence of extrahepatic recurrence were associated with a
significant difference in survival after initial hepatectomy (P = 0.0217).
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